• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Mustang Bio Inc.

    4/14/25 12:15:13 AM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBIO alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: April 11, 2025
    Accession Number: 0001104659-25-032236
    Submission Type: POS AM
    CIK: 0001680048
    Company Name: MUSTANG BIO, INC.
    File Number: 333-284299
    Get the next $MBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MBIO

    DatePrice TargetRatingAnalyst
    1/24/2022$13.00 → $6.00Buy
    B. Riley Securities
    More analyst ratings

    $MBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

      WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1). On February 26, 2025, Mustang received formal notice from Nasdaq confirming that the Company has satisfied the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). As previously disclosed, the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule

      3/5/25 4:15:15 PM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

      WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a Delaware corporation ("AbbVie"), for $1.0 million. Mustang has relocated its corporate headquarters to 95 Sawyer Road, Waltham, Massachusetts. Mustang expects to continue to rely on its academic part

      2/27/25 4:05:27 PM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

      WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing. In addition, as a result of the closing of the public offering announced by the Company on February 10, 2025, the Company believes that it has a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market as required by Nasdaq Listing Rule 5550(b)(1). The Company is awaiting a formal compliance determin

      2/11/25 4:10:30 PM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mustang Bio Inc.

      SC 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)

      11/14/24 4:21:44 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Mustang Bio Inc.

      SC 13D/A - MUSTANG BIO, INC. (0001680048) (Subject)

      6/28/24 4:26:23 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Mustang Bio Inc.

      SC 13G - MUSTANG BIO, INC. (0001680048) (Subject)

      2/14/24 3:42:37 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO and Interim CFO Litchman Manuel Md covered exercise/tax liability with 27 shares, decreasing direct ownership by 2% to 1,634 units (SEC Form 4)

      4 - MUSTANG BIO, INC. (0001680048) (Issuer)

      4/28/25 4:30:13 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Fortress Biotech, Inc. was granted 67,806 shares, increasing direct ownership by 52% to 198,858 units (SEC Form 4)

      4 - MUSTANG BIO, INC. (0001680048) (Issuer)

      4/2/25 4:05:14 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Fortress Biotech, Inc. claimed ownership of 6,552,784 shares (SEC Form 3)

      3 - MUSTANG BIO, INC. (0001680048) (Issuer)

      1/3/25 4:20:31 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBIO
    Financials

    Live finance-specific insights

    See more
    • Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

      Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi

      8/14/23 4:01:50 PM ET
      $ATXI
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

      95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of Hematology (ASH) Annual Meeting Key opinion leader conference call on Thursday, December 16, 2021, at 2:30 p.m. EST WORCESTER, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced updated data from the ongoing Phase 1/2 clinical trial of MB-106,

      12/13/21 9:00:00 AM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBIO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mustang Bio Inc.

      SCHEDULE 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)

      5/9/25 4:03:11 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mustang Bio Inc.

      EFFECT - MUSTANG BIO, INC. (0001680048) (Filer)

      4/14/25 12:15:13 AM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Mustang Bio Inc.

      POS AM - MUSTANG BIO, INC. (0001680048) (Filer)

      4/4/25 4:30:31 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities reiterated coverage on Mustang Bio with a new price target

      B. Riley Securities reiterated coverage of Mustang Bio with a rating of Buy and set a new price target of $6.00 from $13.00 previously

      1/24/22 8:55:18 AM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Mustang Bio with a new price target

      BTIG Research initiated coverage of Mustang Bio with a rating of Buy and set a new price target of $11.00

      5/18/21 6:47:29 AM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care